Profile: StemCells Inc (STEM.OQ)
24 Jun 2016
StemCells, Inc. (StemCells), incorporated on August 2, 1988, is engaged in the research, development and commercialization of stem cell therapeutics. The Company is focused on developing and commercializing stem and progenitor cells as the basis for therapeutics and therapies. The Company's lead product development program is its central nervous system (CNS) Program, in which it is developing applications for HuCNS-SC cells, its human neural platform technology. It is in clinical development with its HuCNS-SC cells for a range of diseases and disorders of the central nervous system, which consists of the brain, spinal cord and eye.
The Company has completed Phase I clinical trial for Pelizeaus-Merzbacher Disease. It has also completed the Phase I clinical trial for Neuronal Ceroid Lipofuscinosis (also known as Batten disease). It has completed the Phase I/II clinical trial in multiple sites for chronic spinal cord injury. The Company is conducting Pathway Study, a Phase II proof-of-concept clinical trial using its HuCNS-SC cells for the treatment of cervical spinal cord injury (SCI).
The Company is conducting a Phase I/II clinical trial to evaluate the safety and preliminary efficacy of its HuCNS-SC cells as a treatment for dry age-related macular degeneration (AMD). It has conducted a Radiant Study, which is a Phase II randomized, controlled proof-of-concept study, designed to evaluate both the safety and efficacy of its HuCNS-SC cells for the treatment of geographic atrophy (GA).
3155 PORTER DRIVE
PALO ALTO CA 94304
Company Web Links
- StemCells to wind down operations after ending mid-stage study
- UPDATE 2-StemCells to wind down operations after ending mid-stage study
- StemCells terminates mid-stage study; to wind down operations
- BRIEF-StemCells Inc files for rights offering for up to $30 mln
- BRIEF-StemCells announces 1-for-12 reverse stock split